Know Cancer

or
forgot password

A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC


Phase 2
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non Small Cell Lung

Thank you

Trial Information

A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC


Inclusion Criteria:



- Histologically of cytologically confirmed non small cell lung cancer

- No prior chemotherapy or radiation

- No prior malignancy

Exclusion Criteria:

- Pregnant or breastfeeding

- Serious concomitant systemic disorder

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Complete pathological response

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Investigator Role:

Study Director

Investigator Affiliation:

Eli Lilly and Company

Authority:

United States: Food and Drug Administration

Study ID:

5489

NCT ID:

NCT00191230

Start Date:

September 2001

Completion Date:

July 2006

Related Keywords:

  • Carcinoma, Non Small Cell Lung
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung

Name

Location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Chapel Hill, North Carolina